scholarly journals Remote multiple intracranial hemorrhage in multiple metastatic lung adenocarcinoma following decompression of posterior fossa lesion: Unknown cause

2015 ◽  
Vol 06 (04) ◽  
pp. 583-585
Author(s):  
Subhas Konar ◽  
R. Arun Babu ◽  
Dhaval P. Shukla ◽  
B Indira Devi
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Surgical Resection ◽  
Posterior Fossa ◽  
Intracranial Hemorrhage ◽  
Surgical Decompression ◽  
Cerebral Metastasis ◽  
Metastatic Lesions ◽  
Metastatic Lung ◽  
Single Lesion

ABSTRACTCerebral metastasis can present with hemorrhage. However, multiple hemorrhages in metastatic lesions following surgical decompression of a single lesion are never reported. We report a case of cerebral metastasis from lung cancer that developed multiple hemorrhages in supratentorial metastatic lesions following surgical resection of an infratentorial lesion.

Surgical treatment of cerebral metastases from lung cancer

1971 ◽  
Vol 35 (4) ◽  
pp. 416-420 ◽  
Author(s):  
Edwin E. MacGee
Keyword(s):  
Lung Cancer ◽  
Surgical Treatment ◽  
Operative Mortality ◽  
Cerebral Metastases ◽  
Cerebral Metastasis ◽  
Metastatic Lung Cancer ◽  
Content Type ◽  
Intracranial Surgery ◽  
Metastatic Lung ◽  
Fine Print

✓ Results in 27 cases of intracranial surgery for metastatic lung cancer are evaluated with regard to both the quality and duration of survival; 56% of the patients lived more than 1 year, with the longest survivor still living 32 months after operation. The operative mortality was 26%. These data suggest that intracranial surgery is worthwhile in patients with lung cancer when the cerebral metastasis is either solitary or single.

EGFR TKI Combined with PD1 Inhibitor for EGFR Mutated Lung Cancer with Breast Metastasis

2021 ◽  
Author(s):  
Xuyu Gu ◽  
Chanchan Gao ◽  
Longfei Wang ◽  
Shiya Zheng
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Left Breast ◽  
Axillary Lymph ◽  
Breast Metastasis ◽  
Lung Cancer Patients ◽  
Metastatic Lung ◽  
New Ideas ◽  
Recurrent Pleural Effusion ◽  
Egfr Tki

Abstract Background: Lung adenocarcinoma with breast metastasis is rare. In the present study, a case of an advanced patient with breast metastasis from lung adenocarcinoma with EGFR 21 exon p.L858R mutation who underwent EGFR TKI combined with PD1 inhibitor is reported.Case presentation: A 62-year-old female patient diagnosed with lung adenocarcinoma who had undergone six times disease progress and breast metastasis in fifth-time disease progress.The patient underwent left breast puncture and axillary lymph node in ultrasound-guided and the postoperative pathological diagnosis of metastatic lung adenocarcinoma was confirmed. And then gene detection showed EGFR 21 exon p.L858R mutation. Breast metastasis from lung adenocarcinoma was diagnosed and the patient is being treated with Almonertinib combined with PD1 inhibitor.Conclusion: Breast metastasis is rare and lung adenocarcinoma might be the primary disease. Gene indection is important. And for lung cancer patients with recurrent pleural effusion, visit of the breast should be included in the follow-up process. In addition, the treatment model of interspersed immunotherapy after EGFR resistance has brought new ideas for the treatment of lung cancer with breast metastasis.

scholarly journals Almonertinib in the treatment of lung cancer with breast metastasis: a case report

2020 ◽  
Author(s):  
Xuyu Gu ◽  
Chanchan Gao ◽  
Longfei Wang ◽  
Shiya Zheng
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Left Breast ◽  
Axillary Lymph ◽  
Breast Metastasis ◽  
Gene Detection ◽  
Lung Cancer Patients ◽  
Metastatic Lung ◽  
Recurrent Pleural Effusion

Abstract BackgroundLung adenocarcinoma with breast metastasis is rare. In the present study, a case of an advanced patient with breast metastasis from lung adenocarcinoma with EGFR 21 exon p.L858R mutation who underwent TKI-inhibitors is reported.Case presentationA 62-year-old female patient diagnosed with lung adenocarcinoma who had undergone seven times disease progress and breast metastasis in sixth time disease progress.The patient underwent left breast puncture and axillary lymph node in ultrasound-guided and the postoperative pathological diagnosis of metastatic lung adenocarcinoma was confirmed. And then gene detection showed EGFR 21 exon p.L858R mutation. Breast metastasis for lung adenocarcinoma was diagnosed and the patient are being treated with Almonertinib.ConclusionBreast metastasis is rare and lung adenocarcinoma might be the primary disease. Gene indection is important. And for lung cancer patients with recurrent pleural effusion, visit of the breast should be included in the follow-up process.

Targeting β-tubulin/CCT-β complex induces apoptosis and suppresses migration and invasion of highly metastatic lung adenocarcinoma

2019 ◽  
Vol 41 (5) ◽  
pp. 699-710 ◽  
Author(s):  
Yan-Jin Liu ◽  
Yu-Ju Chang ◽  
Yu-Ting Kuo ◽  
Po-Huang Liang
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Cancer Cells ◽  
Prognostic Marker ◽  
Epithelial Mesenchymal Transition ◽  
Lung Cancer Cell Line ◽  
Migration And Invasion ◽  
Mesenchymal Transition ◽  
Metastatic Lung ◽  
Β Tubulin

Abstract Metastasis, the movement of cancer cells from one site to another, is responsible for the highest number of cancer deaths, especially in lung cancer patients. In this study, we first identified a prognostic marker of lung adenocarcinoma, TCP-1 β subunit (chaperonin-containing TCP-1β; CCT-β). We showed a compound that disrupted the interaction of CCT-β with β-tubulin killed a highly metastatic non-small cell lung cancer cell line CL1-5 through inducing Endoplasmic reticulum stress and caspases activation. Moreover, at the dosage of EC20, the compound inhibited migration and invasion of the lung cancer cells by suppressing matrix metalloproteinase (MMP)-2/9 and epithelial–mesenchymal transition (EMT)-related proteins through downregulating mitogen-activated protein kinases (MAPKs), Akt/β-catenin and integrin–focal adhesion kinase signaling pathways. Unlike the anticancer drugs, such as Taxol, that target the adenosine triphosphate site of β-tubulin, this study reveals a therapeutic target, β-tubulin/CCT-β complex, for metastatic human lung adenocarcinoma. The study demonstrated CCT-β as a prognostic marker. Targeting β-tubulin/CCT-β complex caused apoptosis and inhibited invasion/migration of CCT-β overexpressed, highly metastatic lung adenocarcinoma.

Leukemoid reaction causing arterial thrombus in a patient with lung adenocarcinoma

2020 ◽  
Vol 13 (10) ◽  
pp. e235389
Author(s):  
Zena Chahine ◽  
Yazan Samhouri ◽  
Thejus Jayakrishnan ◽  
Dulabh Monga
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Cancer Progression ◽  
Venous Stasis ◽  
Leukemoid Reaction ◽  
Painful Ulceration ◽  
Metastatic Lung ◽  
Arterial Insufficiency ◽  
Wbc Count ◽  
The Right

A leukemoid reaction is typically defined as white blood cell (WBC) count >50×109/L, predominantly neutrophil precursors, that are not due to tumour involvement in the bone marrow and not derived from clones. Leukemoid reactions associated with malignancy, known as paraneoplastic leukemoid reactions, are less common and are most notably seen with non-small cell lung cancer. A 64-year-old woman presented with right leg painful ulceration. On examination, she had multiple venous stasis ulcers more severe on the right, with no palpable pulses in her lower extremities. Her WBC count was 124×109/L and platelets were 517×109/L. Arterial dopplers showed limb-threatening arterial insufficiency which prompted right femoral endarterectomy. Few months earlier she was diagnosed with metastatic lung adenocarcinoma to the bone and she had leukemoid reaction with WBC 43.920× 109/L with 90% neutrophils. Repeat imaging showed progression of her malignancy and she passed shortly after. Inflammation is a key element of carcinogenesis and cancer progression. Among the different tumours, lung cancer is a non-haematologic malignancy that is most closely associated with leucocytosis. Some studies have found that leucocytosis was significantly associated with metastasis and shorter survival irrespective of other factors such as age or sex. The mechanism remains unclear however elevated levels of granulocyte colony-stimulating factor (CSF), granulocyte macrophage-CSF and interleukin 6 have been linked to this phenomena. The degree of leucocytosis seen in our patient is suggestive of CSF production leading to a paraneoplastic leukemoid reaction.

scholarly journals 1.2 Cm Lung Nodule Developed into Metastatic Lung Adenocarcinoma in Two Years in Patient Low Socioeconomic Status

2020 ◽  
Vol 2 (2) ◽  
pp. 1-2
Author(s):  
Mukesh Kumar ◽  
◽  
Fnu Sonia ◽  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Socioeconomic Status ◽  
Lung Adenocarcinoma ◽  
Low Socioeconomic Status ◽  
Lung Nodule ◽  
Stage Iv ◽  
Metastatic Lung ◽  
Size Growth

Lung cancer is number one cause of cancer mortality in United States both in men and women. Lung cancer is uncommon in patients younger than 35 years with no smoking and family history. Malignancy from lung nodule depends on size, growth rate, borders, calcification and location. Appropriate follow up for lung nodules in older patient with risk factors has been well described in literature based on various researches. However there is very limited data regarding follow up and management of lung nodule in younger patient with risk factors. We describe a patient who was 30 year old when he presented with acute appendicitis and incidentally found to have lung nodule of 1.2 cm. It was decided that patient should follow up as an outpatient for lung nodule. As patient was uninsured with poor socioeconomic he never followed up as outpatient. After 2 years patient was diagnosed with stage IV lung adenocarcinoma and died shortly after. Guidelines should be used in the proper clinical context as a tool to help with patient management, though exceptions always exist. Some expert believe lung nodule between 8-30 mm in patient with poor follow-up due to socioeconomic status, psychological issues, or young age should get complete resection of nodule.

scholarly journals Cutaneous Metastases from Lung Adenocarcinoma

2020 ◽  
Vol 2020 ◽  
pp. 1-3
Author(s):  
Yu Wang ◽  
Ruzeng Xue
Keyword(s):  
Lung Cancer ◽  
Skin Biopsy ◽  
Lung Adenocarcinoma ◽  
Left Breast ◽  
Cutaneous Metastases ◽  
Presenting Symptoms ◽  
Metastatic Lung ◽  
Nodular Lesions ◽  
One Year ◽  
Heterogeneous Tumor

Cutaneous metastases are unusual presenting symptoms of lung cancer. Therefore, they are prone to be misdiagnosed and missed. The report describes a case of a forty-nine-year-old female with painful zosteriform rashes showing multiple vesicle-like papules localized on the left breast for 10 days. The patient had been diagnosed as lung adenocarcinoma at the department of oncology one year ago. Skin biopsy revealed blue nodular lesions in the dermis, composed of clustered heterogeneous tumor cells with glandular formation. Immunohistochemical stains confirmed the diagnosis of metastatic lung adenocarcinoma.

scholarly journals Dyspnea in an HIV Patient: A Not so Typical Presentation of Lung Adenocarcinoma

2020 ◽  
Vol 8 ◽  
pp. 232470962092787
Author(s):  
Anthony Kunnumpurath ◽  
Christopher Bryan Huang ◽  
Diana Jacob
Keyword(s):  
Lung Cancer ◽  
Pericardial Effusion ◽  
Lung Adenocarcinoma ◽  
Antiretroviral Treatment ◽  
African American Female ◽  
Younger Age ◽  
Metastatic Lung ◽  
Common Etiology ◽  
Hiv Negative

Dyspnea in a HIV patient often warrants an extensive workup. The most common etiology of this presentation is likely due to an infectious etiology. However, with the introduction of antiretroviral treatment, non–AIDS-defining illness including malignancies are increasingly being reported. We report the case of a 46-year-old African American female, nonsmoker who presented with dyspnea and found to have pericardial effusion. In patients with HIV presenting with dyspnea, pericardial effusion should be considered among the differential diagnosis, more so in patients in whom infectious etiologies have been ruled out. Further workup, including imaging and biopsy, revealed that our patient had metastatic lung adenocarcinoma. The introduction of antiretroviral treatment has significantly reduced mortality for those with AIDS from AIDS-defining illness and malignancies. However, the incidence of non–AIDS-defining malignancies like lung adenocarcinoma (most common non–AIDS-defining malignancy) is being increasingly reported. Lung adenocarcinoma often presents at a younger age in patients with HIV than the general population. Smoking rates are higher in patients with HIV and may be a contributing factor to the early onset of lung cancer; however, other factors such as long-term medications and immunomodulation in HIV may also play a role. Prognosis is also worse for HIV-positive patients having lung cancer compared with those who are HIV negative, even at a similar stage of cancer.

scholarly journals Cardiac intraventricular mass from lung adenocarcinoma

2017 ◽  
Vol 23 (1) ◽  
pp. 9-10
Author(s):  
Daniel Grados-Saso ◽  
Isaac Lacambra ◽  
Ana Callejo ◽  
Guillermo Pinillos ◽  
Jara Gayán ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Cardiac Involvement ◽  
3D Echocardiography ◽  
Metastatic Lung Cancer ◽  
Cancer Disease ◽  
Intracardiac Mass ◽  
Metastatic Lung

Summary We present a sole intracardiac mass with no other cardiac involvement in a patient with metastatic lung cancer disease. This mass can be well characterized by advanced 3D echocardiography and echocardiographic contrast.

scholarly journals Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879V

2018 ◽  
Author(s):  
Xu Zhang ◽  
Khoa Dang Nguyen ◽  
Paul Rudnick ◽  
Nitin Roper ◽  
Emily Kawaler ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Lung Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Lung Adenocarcinoma ◽  
Mass Spectrometry Data ◽  
Patient Specific ◽  
Metastatic Site ◽  
Metastatic Lung ◽  
Metastatic Sites

AbstractLung cancer is the leading cause of cancer death both in men and women. Tumor heterogeneity is an impediment to targeted treatment of all cancers, including lung cancer. Here, we sought to characterize changes in tumor proteome and phosphoproteome by longitudinal, prospective collection of tumor tissue of an exceptional responder lung adenocarcinoma patient who survived with metastatic lung adenocarcinoma for more than seven years with HER2-directed therapy in combination with chemotherapy. We employed “Super-SILAC” and TMT labeling strategies to quantify the proteome and phosphoproteome of a lung metastatic site and ten different metastatic progressive lymph nodes collected across a span of seven years, including five lymph nodes procured at autopsy. We identified specific signaling networks enriched in lung compared to the lymph node metastatic sites. We correlated the changes in protein abundance with changes in copy number alteration (CNA) and transcript expression. To further interrogate the mass spectrometry data, patient-specific database was built incorporating all the somatic variants identified by whole genome sequencing (WGS) of genomic DNA from the lung, one lymph node metastatic site and blood. An extensive validation pipeline was built for confirmation of variant peptides. We validated 360 spectra corresponding to 55 germline and 6 somatic variant peptides. Targeted MRM assays demonstrated expression of two novel variant somatic peptides, CDK12-G879V and FASN-R1439Q, with expression in lung and lymph node metastatic sites, respectively. CDK12 G879V mutation likely results in a nonfunctional CDK12 kinase and chemotherapy susceptibility in lung metastatic sites. Knockdown of CDK12 in lung adenocarcinoma cells results in increased chemotherapy sensitivity, explaining the complete resolution of the lung metastatic sites in this patient.

Sign in / Sign up

Export Citation Format

Share Document